Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies

Mathew Clement*, James Pearson, Stephanie Gras, Hugo A van den Berg, Anya Lissina, Sian Llewellyn-Lacey, Mark Willis, Tamsin Dockree, James E McLaren, Julia Ekeruche-Makinde, Emma Gostick, Neil P Robertson, Jamie Rossjohn, Scott R Burrows, David A Price, Susan Wong, Mark Peakman, Ania Skowera, Linda Wooldridge

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

10 Citations (Scopus)
349 Downloads (Pure)

Abstract

CD8+ T-cells play a role in the pathogenesis of autoimmune diseases such as multiple sclerosis and type 1 diabetes. However, drugs that target the entire CD8+ T-cell population are not desirable because the associated lack of specificity can lead to unwanted consequences, most notably an enhanced susceptibility to infection. Here, we show that autoreactive CD8+ T-cells are highly dependent on CD8 for ligand-induced activation via the T-cell receptor (TCR). In contrast, pathogen-specific CD8+ T-cells are relatively CD8-independent. These generic differences relate to an intrinsic dichotomy that segregates self-derived and exogenous antigen-specific TCRs according to the monomeric interaction affinity with cognate peptide-major histocompatibility complex class I (pMHCI). As a consequence, “blocking” anti-CD8 antibodies can suppress autoreactive CD8+ T-cell activation in a relatively selective manner. These findings provide a rational basis for the development and in vivo assessment of novel therapeutic strategies that preferentially target disease-relevant autoimmune responses within the CD8+ T-cell compartment.
Original languageEnglish
Article number35332
Number of pages14
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 17 Oct 2016

Keywords

  • Autoimmunity
  • CD8 T-cells
  • novel therapy
  • type 1 diabetes

Fingerprint Dive into the research topics of 'Targeted suppression of autoreactive CD8<sup>+</sup> T-cell activation using blocking anti-CD8 antibodies'. Together they form a unique fingerprint.

Cite this